ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00530478
Recruitment Status : Unknown
Verified July 2007 by Samsung Medical Center.
Recruitment status was:  Recruiting
First Posted : September 17, 2007
Last Update Posted : September 17, 2007
Sponsor:
Information provided by:
Samsung Medical Center

Brief Summary:
The purpose of this study is to demonstrate the efficacy and safety of donepezil on the recovery of cognitive function in patients with stroke and to delineate the neurophysiologic mechanisms of the therapeutic effect of donepezil on the recovery of cognitive network using functional neuroimaging technique.

Condition or disease Intervention/treatment Phase
Stroke Drug: Donepezil Not Applicable

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Ischemic stroke in the territory of right or left middle cerebral artery
  • Post-onset duration of the recent-onset stroke is over 3 months
  • Cognitive deficit ranged from 10 to 26 by minimal mental status examination (MMSE) score
  • Disturbance in activities of daily living (ADL) ranged 0.5 ~ 2.0 by clinical dementia rating (CDR) scale

Exclusion Criteria:

  • Severe internal carotid artery stenosis on the lesion side
  • Cardiac pacemaker or intracranial metal insertion
  • Post-stroke seizure disorder or any evidence of epileptic spikes on electroencephalography (EEG)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00530478


Contacts
Contact: Yun-Hee Kim, MD, PHD 82-2-3410-2818 yunkim@smc.samsung.co.kr

Locations
Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Yun-Hee Kim, MD, PHD    82-2-3410-2818    yunkim@smc.samsung.co.kr   
Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Suk Hoon Ohn, MD, MS Samsung Medical Center
Principal Investigator: Yun Hee Park, MD Samsung Medical Center

ClinicalTrials.gov Identifier: NCT00530478     History of Changes
Other Study ID Numbers: 2006-04-023
First Posted: September 17, 2007    Key Record Dates
Last Update Posted: September 17, 2007
Last Verified: July 2007

Keywords provided by Samsung Medical Center:
Donepezil
Stroke
Cognitive function
Cognitive neural network

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents